Skip to main content

Addtech Acquires Reagent, Instrument Firm BioNordika

NEW YORK (GenomeWeb News) – Swedish firm Addtech Life Science today announced it has acquired BioNordika Holding.

Addtech Life Science is a business area in the Addtech Group. BioNordika Holding is the parent company of the BioNordika Group, which markets reagents and instruments for biomedical research, primarily to the pharmaceutical industry and public institutions.

BioNordika Group has subsidiaries in Denmark, Estonia, Finland, Norway, and Sweden. It has 24 employees and SEK80 million ($11.8 million) in sales.

The purchase is expected to be complementary to Addtech Life Science's Diagnostic Business Unit, which sells reagents and equipment to healthcare laboratories in the Nordic region.

The deal, which closes today, is anticipated to be "marginally" accretive to Addtech Life Science's earnings per share in the current year, it said.

Terms of the acquisition were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.